{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2012"],"condition":["Triple Negative Breast, Prostate, Colorectal, Gastric, Ovarian, Pancreatic, Esophageal, Soft Tissue Sarcoma, and Head & Neck Cancer","Sarcoma"],"disease":["Sarcoma","Triple Negative Breast, Prostate, Colorectal, Gastric, Ovarian, Pancreatic, Esophageal, Soft Tissue Sarcoma, And Head & Neck Cancer"],"study_type":["Observational"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2130178"],"location":["United States"],"study_start_month":["7"],"repository":["ECRIN MDR"],"study_status":["Terminated"],"additional_accession":[]},"is_claimable":false,"name":"Study of 124I-NM404 in Advanced Solid Malignancies","description":"The purpose of this study is to assess the use of investigational compound 124I-NM404 for accurate detection and characterization of a wide variety of solid primary and metastatic malignancies anywhere in the body.","dates":{"creation":"2012-07-15"},"accession":"2130178","cross_references":{"ClinicalTrials___gov":["NCT01662284"]}}